CN114380863B - 金鸡纳碱衍生的nnp配体及其制备方法与用途 - Google Patents

金鸡纳碱衍生的nnp配体及其制备方法与用途 Download PDF

Info

Publication number
CN114380863B
CN114380863B CN202111546885.1A CN202111546885A CN114380863B CN 114380863 B CN114380863 B CN 114380863B CN 202111546885 A CN202111546885 A CN 202111546885A CN 114380863 B CN114380863 B CN 114380863B
Authority
CN
China
Prior art keywords
ligand
nnp
nmr
cdcl
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111546885.1A
Other languages
English (en)
Other versions
CN114380863A (zh
Inventor
刘心元
程永峰
文汉涛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Southern University of Science and Technology
Original Assignee
Southern University of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern University of Science and Technology filed Critical Southern University of Science and Technology
Priority to CN202111546885.1A priority Critical patent/CN114380863B/zh
Publication of CN114380863A publication Critical patent/CN114380863A/zh
Application granted granted Critical
Publication of CN114380863B publication Critical patent/CN114380863B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2442—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/40—Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions
    • B01J2231/49—Esterification or transesterification
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/10—Complexes comprising metals of Group I (IA or IB) as the central metal
    • B01J2531/16—Copper

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明属于有机化学配体领域，具体是一种金鸡纳碱衍生的NNP配体，具有通式Ⅰ的结构或其互变异构体、对映异构体、非对映异构体：

Description

金鸡纳碱衍生的NNP配体及其制备方法与用途
技术领域
本发明属于有机化学配体领域，具体是一种金鸡纳碱衍生的NNP配体及其制备方法与用途。
背景技术
金鸡纳碱(奎宁)及其类似物是一类在自然界中广泛存在的天然手性产物，基于其空间结构复杂以及多配位点等特点，之前一直被用于有机小分子催化的不对称反应中。近年来，随着过渡金属不对称催化领域快速发展，各类新手性配体骨架的需求日益增加。奎宁及其类似物衍生的氮氮磷配体含有一个三级胺、一个三价磷以及一个酰胺结构(在碱的作用下可以被去质子化生成酰胺负离子)，这类配体不仅可以提供氢键等作用，还可以与过渡金属配位，产生手性金属络合物用以催化反应。
肌醇磷酸酯广泛纯在于动植物及微生物体内，在细胞信号传导中起到至关重要的作用。手性肌醇磷酸酯的合成在生物化学中非常重要，目前手性肌醇磷酸酯的合成主要是通过经典的拆分方法，其催化不对称合成的报道非常少，并且主要集中于1,3-去对称化，而4,6-去对称化仅有一例报道，Miller等人报道了多肽催化的1,3,5-位保护的肌醇底物的4,6-去对称化不对称磷酰基化反应，但是得到的6位羟基磷酰基化的产物ee值并不是十分理想(71％ee)，此外，由于使用的是多肽类催化剂，其催化剂的对映异构体难以获得，因此难以得到4位羟基磷酰基化为主的产物，如下式所示：
由于上述生物催化存在的一些问题，因此发展新的化学催化体系来实现肌醇的4,6-去对称化反应，以高对映选择性得到4位/6位羟基保护的产物是非常有必要的。
发明内容
本发明的目的是提供一种结构新颖的金鸡纳碱衍生的NNP配体。
本发明的另一目的是提供该NNP配体的制备方法。
本发明的另一目的是将该NNP配体用于肌醇4,6-去对称化不对称磺酰基化反应。
为达到上述目的之一，本发明采用以下技术方案；
本发明的第一方面，一种金鸡纳碱衍生的NNP配体，具有通式Ⅰ的结构或其互变异构体、对映异构体、非对映异构体：
其中，R选自苯基、萘基，或者烷基、烷氧基、三氟甲基取代的苯基。
进一步地，所述R选自苯基、萘基，或者(C1～C4)烷基、(C1～C4)烷氧基、三氟甲基取代的苯基。
进一步地，所述R选自苯基、萘基，或者甲基、异丙基、叔丁基、甲氧基、三氟甲基取代的苯基。
进一步地，所述R选自苯基、2-萘基、4-甲基苯基、4-叔丁基苯基、4-甲氧基苯基、3,5-二三氟甲基苯基、3,5-二叔丁基苯基、2,4,6-三甲基苯基、2,4,6-三异丙基苯基。
本发明的第二方面，一种NNP配体的制备方法，包括以下步骤：
化合物S1和亚磷酸二乙酯反应，得到中间体S2；
中间体S2脱氧得到中间体S3；
中间体S3和邻溴苯甲醛反应，得到中间体S4；
中间体S4和奎宁衍生物S5进行缩合反应，得到产物；
R如权利要求1～4所定义。
本发明的第三方面，NNP配体在肌醇不对称磺酰基化反应的应用。
进一步地，所述肌醇不对称磺酰基化反应包括：
使用NNP配体，使化合物A与R3SO2Cl反应制备化合物B的步骤，
其中，R1为氢、烷基或芳基；R2为硅基、苄基、酰基或磺酰基；R3为烷基、环烷基或芳基。
进一步地，R1为氢、(C1～C4)烷基或苯基；R2为硅基或酰基；R3为(C4～C7)环烷基或苯基。
进一步地，R1为甲基或苯基；R2为乙酰基或TBS；R3为环己基或苯基。
进一步地，所述肌醇不对称磺酰基化反应加入双三苯基膦硼氢化亚铜、碳酸银和分子筛。
进一步地，所述化合物A与R3SO2Cl的摩尔比为1:(1～3)。
进一步地，相对于化合物A，所述双三苯基膦硼氢化亚铜的用量为1～30mol％；所述L配体的用量为2～30mol％；所述碳酸银的用量为30～100mol％，即当化合物A的用量为1mol时，双三苯基膦硼氢化亚铜的用量为0.01～0.3mol，L配体的用量为0.02～0.3mol，碳酸银的用量为0.3～1mol。
进一步地，所述肌醇不对称磺酰基化反应的温度为-10℃～室温，溶剂为二氯甲烷、二氯乙烷、氯仿或四氯化碳。
本发明所用的“烷基”指饱和脂肪族烃基团，其为包含1至20个碳原子的直链或支链基团，优选含有1至12个碳原子的烷基，更优选含有1至6个碳原子的烷基。烷基基团的实例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基、叔丁基、戊基、2-戊基、异戊基、新戊基、己基、2-己基、3-己基、3-甲基戊基。
本发明所用的“烷氧基”是指-O-烷基基团，其中烷基如上所定义。本文所用烷氧基的实例包括但不限于甲氧基、乙氧基、正丙氧基、异丙氧基、正丁氧基和叔丁氧基。烷氧基还包括取代烷氧基。烷氧基可任选被卤素取代一次或多次。
本发明所用的“环烷基”指非芳族碳环，其通常具有3至8个环碳原子。所述环可以是饱和的或具有一个或更多个碳-碳双键。环烷基基团的实例包括环丙基、环丁基、环戊基、环戊烯基、环己基、环己烯基或环庚基。
本发明所用的“芳基”是指5～12个碳原子的全碳单环或稠合多环基团，具有完全共轭的π电子系统。芳基的非限制性实例有：苯环、萘环、蒽环。
本文所用的“苄基”指C6H5CH2-。
本文所用的“磺酰基”指-S(＝O)2-，磺酰基的非限制性实例有：对甲苯磺酰基、对溴苯磺酰基、硝基苯磺酰基、甲磺酰基、三氟甲磺酰基、5-(二甲氨基)萘-1-磺酰基。
本文所用的“酰基”指R-C(＝O)-，R指烷基、芳基，烷基、芳基的定义如本文所述，酰基的非限制性实例有：邻苯二甲酰基、特戊酰基、乙酰基、苯甲酰基。
本文所用的“硅基”指R1R2R3Si-O-，R1、R2、R3指烷基或苯基，烷基的定义如本文所述，硅基的非限制性实例有：三甲基硅基(TMS)、叔丁基二苯基硅基(TBDPS)、叔丁基二甲基硅基(TBS/TBDMS)和三异丙基硅基(TIPS)。
本文所述“取代的苯基”的“取代”可以是单取代，也可以是多取代，“取代的苯基”包括：(1)苯环有一个取代基；(2)苯环有两个及两个以上相同或不同取代基。取代的位置可以是苯环2、3、4、5、6的任意位置。
本发明具有以下有益效果：
本发明合成了一类结构新颖的金鸡纳碱衍生的NNP配体，具有烷基胺结构，可以将之用于催化肌醇不对称磺酰基化反应，在立体选择性与反应效率方面都具有优势，反应的收率和对映选择性高(收率60％以上，对映体过量ee值可达91％)，能获得很高对映体过量的产物，同时改变手性配体的绝对构型，则可以得到产物的另一个对映异构体，反应条件比较温和，可重复性较好，易于进行工业化扩大合成，具有很好的应用前景。
具体实施方式
除非另有说明，化学品均购自商业化产品并且不经进一步纯化。实验中使用的二氯甲烷等溶剂均为无水溶剂。薄层色谱分析(TLC)使用60F254硅胶板。硅胶柱层析使用青岛海洋硅胶(粒径0.040-0.063mm)。TLC显色采用UV光(254nm)或碘。NMR图谱使用BrukerDPX400或DPX 500核磁共振仪表征，1HNMR为400或500MHz，31PNMR为162MHz，溶剂为氘代氯仿，以四甲基硅烷(TMS)为内标。化学位移的单位是ppm，耦合常数的单位是Hz。在1HNMR中，δ表示化学位移，s表示单峰，d表示双峰，t表示三重峰，q表示四重峰，p表示五重峰，m表示多重峰，br表示宽峰。
实施例1
配体的合成
上述配体可以按照以下路线合成：
步骤1：在0℃下向格式试剂S1(3.0mmol)的四氢呋喃溶液中缓慢滴加亚磷酸二乙酯(1.0mmol)。然后将反应液恢复至室温并继续搅拌12小时。反应完全后，反应液通过硅胶柱色谱(石油醚与乙酸乙酯比例为50:1)直接进行纯化，得到S2(40～80％产率)。
步骤2：在室温下，向S2(1.0mmol)的甲苯溶液中加入三氟甲磺酸铜(0.1mmol)和1,1,3,3-四甲基二硅氧烷TMDS(2.0mmol)。将反应混合物搅拌并加热回流12小时。冷却至室温后，减压条件下除去甲苯溶剂，得到粗产物S3，直接进行下一步反应。
步骤3：将上一步得到的粗产物S3溶解到二甲基亚砜中，随后加入醋酸钯(0.1mmol)、双二苯基膦丙烷(0.1mmol)、二异丙基乙基胺(1.0mmol)和邻溴苯甲醛(1.0mmol)。将反应混合物脱气并加热(100℃)搅拌24小时。冷却至室温并加入乙酸乙酯(100mL)和水(50mL)，有机层用水洗4次后用无水硫酸钠干燥。过滤并真空浓缩。由此获得的残余物通过硅胶柱色谱法(石油醚与乙酸乙酯比例为5:1)纯化，得到S4(50～80％收率)。
步骤4：将S4溶解在乙醇中，加入S5并加热回流10小时，随后冷却至室温并加入硼氢化钠，在室温下反应6小时后加入丙酮(50mL)淬灭反应，真空浓缩后加入二氯甲烷(100mL)和饱和氯化铵(100mL)，有机层用无水硫酸钠干燥，过滤并真空浓缩。由此获得的残余物通过硅胶柱色谱法(石油醚与乙酸乙酯比例为1:1)纯化，得到配体I(40～70％收率)。
配体L1的表征数据：
1H NMR(400MHz,CDCl3)δ9.33(s,1H×0.3),9.00–8.84(m,1H),8.76(s,1H×0.3),8.17–8.15(m,2H+1H×0.3),7.91–7.78(m,1H),7.73–7.69(m,1H+1H×0.3),7.58–7.49(m,1H+1H×0.3),7.35–7.05(m,13H+14H×0.3),6.89–6.80(m,1H+1H×0.3),5.77–5.54(m,1H+1H×0.3),4.98–4.76(m,2H+2H×0.3),4.60(d,J＝9.5Hz,1H),3.98–3.84(m,2H×0.3),3.79(d,J＝12.8Hz,1H),3.51(d,J＝13.1Hz,1H+1H×0.3),3.40(s,1H×0.3),3.23–3.04(m,1H+2H×0.3),3.04–2.76(m,4H),2.76–2.41(m,3H),2.19(s,1H+1H×0.3),1.51(s,4H+2H×0.3),1.20–1.02(m,1H+2H×0.3),0.91–0.63(m,2H)。
13C NMR(100MHz,CDCl3)δ150.6,148.6,148.2,144.7,144.4,141.8,136.9,136.8,136.6,135.7,135.5,133.8,133.7,133.6,133.5,130.4,129.44,129.38,129.0,128.8,128.7,128.5,128.44,128.41,128.34,128.28,127.2,126.2,122.7,120.1,114.1,69.2,62.4,58.3,57.0,56.0,50.0,49.8,40.9,39.9,29.2,28.1,27.5,26.8,25.2。
31P NMR(162MHz,CDCl3)δ-16.3。
配体L2的表征数据：
1H NMR(400MHz,CDCl3)δ9.43(s,1H×0.3),9.10–8.95(m,1H),8.85(s,1H×0.3),8.22–8.11(m,2H+1H×0.3),7.98–7.86(m,1H),7.83–7.69(m,1H+1H×0.3),7.68–7.59(m,1H+1H×0.3),7.54–7.23(m,12H+13H×0.3),7.01–6.86(m,1H+1H×0.3),5.77–5.54(m,1H+1H×0.3),4.98–4.73(m,2H+2H×0.3),4.20(d,J＝9.5Hz,1H),4.08–3.89(m,2H×0.3),3.85(d,J＝12.8Hz,1H),3.61(d,J＝13.1Hz,1H+1H×0.3),3.48(s,1H×0.3),3.34–3.24(m,1H+2H×0.3),3.25–2.95(m,4H),2.89–2.78(m,3H),2.69(s,3H+3H×0.3),2.09(s,1H+1H×0.3),1.70(s,4H+2H×0.3),1.32–1.12(m,1H+2H×0.3),0.95–0.68(m,2H)。
13C NMR(100MHz,CDCl3)δ152.6,148.9,149.2,145.1,145.0,141.9,137.1,137.0,136.9,135.9,135.8,134.0,133.8,133.7,133.6,130.6,129.8,129.5,129.3,128.9,128.9,128.7,128.6,128.5,128.4,128.3,127.6,126.7,122.9,120.4,114.6,69.8,62.7,58.6,57.4,56.5,50.7,49.9,40.9,39.9,29.8,28.5,27.8,27.0,25.8,21.8。
31P NMR(162MHz,CDCl3)δ-16.6。
配体L3的表征数据：
1H NMR(400MHz,CDCl3)δ9.41(s,1H×0.3),9.11–8.98(m,1H),8.87(s,1H×0.3),8.35–8.21(m,2H+1H×0.3),8.14–7.99(m,1H),7.93–7.81(m,1H+1H×0.3),7.74–7.61(m,1H+1H×0.3),7.54–7.33(m,12H+13H×0.3),7.21–6.97(m,1H+1H×0.3),5.86–5.64(m,1H+1H×0.3),4.98–4.81(m,2H+2H×0.3),4.34(d,J＝9.5Hz,1H),4.43–3.98(m,2H×0.3),3.91(d,J＝12.8Hz,1H),3.71(d,J＝13.1Hz,1H+1H×0.3),3.53(s,1H×0.3),3.43–3.24(m,1H+2H×0.3),3.34–2.99(m,4H),2.96–2.86(m,3H),2.72(s,3H+3H×0.3),2.29(s,1H+1H×0.3),1.80(s,4H+2H×0.3),1.42(s,9H+9H×0.3),1.39–1.21(m,1H+2H×0.3),0.96–0.69(m,2H)。
13C NMR(100MHz,CDCl3)δ152.8,148.9,149.2,145.3,145.1,141.9,137.3,137.2,136.9,136.0,135.8,134.4,133.9,133.8,133.7,130.9,129.8,129.8,129.3,129.0,128.9,128.7,128.6,128.5,128.4,128.3,127.8,126.8,123.2,120.1,114.7,69.9,62.9,58.6,57.7,56.9,50.5,49.9,40.9,39.9,35.8,31.4,29.9,28.2,27.9,27.3,25.8。
31P NMR(162MHz,CDCl3)δ-16.2。
配体L4的表征数据：
1H NMR(400MHz,CDCl3)δ9.40(s,1H×0.3),9.00–8.83(m,1H),8.79(s,1H×0.3),8.27–8.18(m,2H+1H×0.3),7.96–7.83(m,1H),7.80–7.72(m,1H+1H×0.3),7.68–7.59(m,1H+1H×0.3),7.38–7.25(m,13H+14H×0.3),6.93–6.84(m,1H+1H×0.3),5.87–5.64(m,1H+1H×0.3),5.01–4.87(m,2H+2H×0.3),4.70(d,J＝9.5Hz,1H),4.26(s,3H),4.12(s,3H×0.3),3.98–3.86(m,2H×0.3),3.82(d,J＝12.8Hz,1H),3.62(d,J＝13.1Hz,1H+1H×0.3),3.51(s,1H×0.3),3.43–3.21(m,1H+2H×0.3),3.12–2.87(m,4H),2.76–2.46(m,3H),2.19(s,1H+1H×0.3),1.51(s,4H+2H×0.3),1.21–1.12(m,1H+2H×0.3),0.91–0.73(m,2H)。
13C NMR(100MHz,CDCl3)δ160.0,152.6,149.6,148.8,145.6,144.9,142.8,137.2,136.8,136.6,135.7,135.6,134.0,133.9,133.7,133.5,131.4,129.8,129.6,129.4,129.2,128.9,128.6,128.5,128.4,128.3,127.2,126.2,123.2,120.5,1144,69.7,62.6,58.7,57.3,56.6,55.9,50.8,49.9,41.3,39.9,29.6,28.3,27.7,26.9,25.5。
31P NMR(162MHz,CDCl3)δ-13.6。
配体L5的表征数据：
1H NMR(400MHz,CDCl3)δ9.66(s,1H×0.3),9.43–8.98(m,1H),8.96(s,1H×0.3),8.57–8.35(m,2H+1H×0.3),7.99–7.86(m,1H),7.55–7.21(m,13H+14H×0.3),6.96–6.87(m,1H+1H×0.3),5.98–5.64(m,1H+1H×0.3),4.98–4.76(m,2H+2H×0.3),4.80(d,J＝9.5Hz,1H),4.01–3.94(m,2H×0.3),3.89(d,J＝12.8Hz,1H),3.71(d,J＝13.1Hz,1H+1H×0.3),3.45(s,1H×0.3),3.27–3.09(m,1H+2H×0.3),3.24–2.79(m,4H),2.76–2.52(m,3H),2.25(s,1H+1H×0.3),1.71(s,4H+2H×0.3),1.43–1.22(m,1H+2H×0.3),0.95–0.73(m,2H)。
13C NMR(100MHz,CDCl3)δ152.6,149.6,148.2,144.7,144.9,142.8,136.9,136.8,136.6,135.9,135.8,133.9,133.8,133.6,133.5,132.4,129.42,129.39,129.1,128.8,128.7,128.6,128.5,128.4,128.3,128.2,127.2,126.5,123.7,120.5,114.6,69.7,62.5,58.2,57.0,56.4,50.7,49.8,40.9,39.9,29.4,28.8,27.5,26.9,25.5。
31P NMR(162MHz,CDCl3)δ-7.3.19F NMR(376MHz,CDCl3)δ-62.97,-63.00。
配体L6的表征数据：
1H NMR(400MHz,CDCl3)δ9.32(s,1H×0.3),9.09–8.98(m,1H),8.83(s,1H×0.3),8.31–8.21(m,2H+1H×0.3),8.11–7.99(m,1H),7.91–7.71(m,1H+1H×0.3),7.69–7.61(m,1H+1H×0.3),7.51–7.31(m,12H+13H×0.3),7.14–6.96(m,1H+1H×0.3),5.66–5.54(m,1H+1H×0.3),4.85–4.71(m,2H+2H×0.3),4.30(d,J＝9.5Hz,1H),4.25–3.98(m,2H×0.3),3.87(d,J＝12.8Hz,1H),3.63(d,J＝13.1Hz,1H+1H×0.3),3.43(s,1H×0.3),3.33–3.24(m,1H+2H×0.3),3.22–2.99(m,4H),2.96–2.88(m,3H),2.71(s,3H+3H×0.3),2.25(s,1H+1H×0.3),1.80(s,4H+2H×0.3),1.40(s,19H+19H×0.3),1.35–1.23(m,1H+2H×0.3),0.96–0.69(m,2H)。
13C NMR(100MHz,CDCl3)δ152.1,148.5,149.2,145.3,145.1,141.4,137.3,137.1,136.5,136.0,135.5,134.1,133.1,133.6,133.5,130.5,129.6,129.5,129.3,129.0,128.7,128.6,128.5,128.4,128.3,127.1,126.2,123.0,120.0,114.1,69.6,62.6,58.3,57.2,56.7,50.1,49.1,40.4,39.5,35.5,31.1,29.1,28.0,27.6,27.0,25.1。
31P NMR(162MHz,CDCl3)δ-16.1。
配体L7的表征数据：
1H NMR(400MHz,CDCl3)δ9.33(s,1H×0.3),9.05–8.95(m,1H),8.81(s,1H×0.3),8.20–8.10(m,2H+1H×0.3),7.91–7.82(m,1H),7.80–7.65(m,1H+1H×0.3),7.64–7.55(m,1H+1H×0.3),7.52–7.33(m,12H+13H×0.3),7.00–6.83(m,1H+1H×0.3),5.74–5.51(m,1H+1H×0.3),4.91–4.70(m,2H+2H×0.3),4.14(d,J＝9.5Hz,1H),4.02–3.81(m,2H×0.3),3.82(d,J＝12.8Hz,1H),3.51(d,J＝13.1Hz,1H+1H×0.3),3.42(s,1H×0.3),3.30–3.20(m,1H+2H×0.3),3.15–2.95(m,4H),2.85–2.75(m,3H),2.70(s,6H+6H×0.3),2.63(s,3H+3H×0.3),2.01(s,1H+1H×0.3),1.70(s,4H+2H×0.3),1.31–1.10(m,1H+2H×0.3),0.91–0.62(m,2H)。
13C NMR(100MHz,CDCl3)δ152.0,148.2,149.0,145.0,144.7,141.5,137.0,136.9,136.6,135.5,135.4,134.5,133.9,133.8,133.1,130.0,129.4,129.3,129.2,128.8,128.5,128.3,128.2,128.0,127.8,127.4,126.4,122.5,120.1,114.0,69.1,62.3,58.5,57.4,56.5,50.7,49.5,40.3,39.7,29.1,28.4,27.7,27.0,25.1,22.3,21.8。
31P NMR(162MHz,CDCl3)δ-16.5。
配体L8的表征数据：
1H NMR(400MHz,CDCl3)δ9.30(s,1H×0.3),9.01–8.83(m,1H),8.74(s,1H×0.3),8.17–8.12(m,2H+1H×0.3),7.94–7.78(m,1H),7.79–7.64(m,1H+1H×0.3),7.59–7.44(m,1H+1H×0.3),7.33–7.08(m,13H+14H×0.3),6.91–6.85(m,1H+1H×0.3),5.79–5.56(m,1H+1H×0.3),4.99–4.78(m,2H+2H×0.3),4.62(d,J＝9.5Hz,1H),3.98–3.82(m,2H×0.3),3.79(d,J＝12.8Hz,1H),3.52(d,J＝13.1Hz,1H+1H×0.3),3.40(s,1H×0.3),3.23–3.04(m,1H+2H×0.3),3.08–2.79(m,4H),2.72–2.46(m,3H),2.52(m,4H+2H×0.3),2.41(m,2H+2H×0.3),2.19(s,1H+1H×0.3),1.68(d,J＝9.1Hz,24H+24H×0.3),1.51(s,12H+12H×0.3),1.21–1.02(m,1H+2H×0.3),0.93–0.61(m,2H)。
13C NMR(100MHz,CDCl3)δ150.3,148.6,148.2,144.6,144.2,141.8,136.6,136.5,136.4,135.4,135.3,133.8,133.7,133.6,133.5,130.2,129.41,129.39,129.0,128.8,128.7,128.5,128.43,128.41,128.32,128.29,127.1,126.0,122.3,120.5,114.0,69.1,62.5,58.3,57.3,56.1,50.1,49.9,40.4,39.6,33.1,29.0,28.2,27.6,26.8,25.2,23.2。31PNMR(162MHz,CDCl3)δ-16.3。
配体L9的表征数据：
1H NMR(400MHz,CDCl3)δ9.35(s,1H×0.3),9.01–8.85(m,1H),8.66(s,1H×0.3),8.27–8.14(m,2H+1H×0.3),7.92–7.77(m,1H),7.72–7.67(m,1H+1H×0.3),7.51–7.41(m,1H+1H×0.3),7.35–7.05(m,17H+17H×0.3),6.85–6.80(m,1H+1H×0.3),5.76–5.52(m,1H+1H×0.3),4.94–4.73(m,2H+2H×0.3),4.61(d,J＝9.5Hz,1H),3.98–3.81(m,2H×0.3),3.75(d,J＝12.8Hz,1H),3.50(d,J＝13.1Hz,1H+1H×0.3),3.41(s,1H×0.3),3.21–3.04(m,1H+2H×0.3),3.02–2.78(m,4H),2.76–2.42(m,3H),2.22(s,1H+1H×0.3),1.55(s,4H+2H×0.3),1.21–1.01(m,1H+2H×0.3),0.96–0.68(m,2H)。
13C NMR(100MHz,CDCl3)δ151.6,147.5,148.4,144.5,144.1,141.3,137.2,136.6,136.5,135.8,135.4,133.4,133.3,133.2,133.1,132.9,132.5,130.1,129.9,129.7,129.1,128.9,128.7,128.5,128.42,128.40,128.38,128.36,127.1,126.7,122.5,120.2,114.5,69.0,62.2,58.6,57.1,56.1,50.4,49.4,40.8,39.5,29.2,28.1,27.5,26.8,25.2。
31P NMR(162MHz,CDCl3)δ-16.9。
实施例2
将实施例1的配体用于肌醇4,6-去对称化不对称磺酰基化反应
向装有搅拌棒、经烘箱干燥的250mL圆底烧瓶装入保护的肌醇底物(1.0g,2.63mmol,1.0eq.)、双三苯基膦硼氢化亚铜(157.8mg,0.26mmol,10mol％)、手性配体L1(179.3mg,0.32mmol,12mol％)、碳酸银(435.5mg,1.58mmol,0.6eq.)、分子筛(0.4g)，然后加入干燥氯仿(50mL)。室温条件下搅拌5分钟后加入苯磺酰氯(0.4mL,3.16mmol,1.2eq.)。室温条件下反应2天，用铺有硅藻土的过滤装置过滤，滤液浓缩并通过硅胶柱色谱纯化(石油醚/乙酸乙酯＝4/1)。得到白色固体(1.07g,产率：78％，ee：91％)。
产物表征数据：
HPLC条件:Chiralcel OD(正己烷/异丙醇＝95/5,流速0.5mL/min,λ＝214nm),tR(major)＝20.81min,tR(minor)＝14.33min。
1H NMR(400MHz,CDCl3)δ8.03–7.92(m,2H),7.77–7.69(m,1H),7.66–7.56(m,4H),7.37–7.30(m,3H),5.25(td,J＝4.0,1.7Hz,1H),4.68–4.64(m,1H),4.44–4.39(m,1H),4.30–4.27(m,1H),4.25(t,J＝1.8Hz,1H),4.19–4.16(m,1H),2.43(d,J＝6.6Hz,1H),0.92(s,9H),0.13(s,3H),0.10(s,3H)。
13C NMR(100MHz,CDCl3)δ136.5,135.3,134.7,129.7,129.6,128.03,127.95,125.3,107.4,75.4,74.6,73.4,69.5,67.5,59.3,25.8,18.2,-4.65,-4.71。
HRMS(ESI)m/z精确质量计算C25H33O8SSi[M+H]+521.1660,实测值521.1660。
将配体L1替换为配体L2～L9，反应结果如下：
可见，本发明的配体用于肌醇4,6-去对称化不对称磺酰基化反应，ee值在80％以上，显著提升了此类反应的对映选择性，是一类良好配体。
实施例3
向装有搅拌棒、经烘箱干燥的250mL圆底烧瓶装入保护的肌醇底物(0.84g,2.63mmol,1.0eq.)、双三苯基膦硼氢化亚铜(157.8mg,0.26mmol,10mol％)、手性配体L1(179.3mg,0.32mmol,12mol％)、碳酸银(435.5mg,1.58mmol,0.6eq.)、分子筛(0.4g)，然后加入干燥氯仿(50mL)。室温条件下搅拌5分钟后加入苯磺酰氯(0.4mL,3.16mmol,1.2eq.)。室温条件下反应2天，用铺有硅藻土的过滤装置过滤，滤液浓缩并通过硅胶柱色谱纯化(石油醚/乙酸乙酯＝4/1)。得到白色固体(0.96g,产率：80％，ee：88％)。
表征数据：
HPLC条件:Chiralcel OD(正己烷/异丙醇＝95/5,流速0.5mL/min,λ＝214nm),tR(major)＝25.55min,tR(minor)＝15.35min。
1H NMR(400MHz,CDCl3)δ7.76–7.66(m,4H),7.31–7.25(m,1H),5.35(td,J＝4.0,1.7Hz,1H),4.78–4.74(m,1H),4.49–4.39(m,1H),4.36–4.37(m,1H),4.25(t,J＝1.8Hz,1H),4.19–4.16(m,1H),2.80(s,3H),2.43(d,J＝6.6Hz,1H),0.92(s,9H),0.13(s,3H),0.10(s,3H)。
13C NMR(100MHz,CDCl3)δ135.0,134.8,129.9,125.0,108.4,76.4,74.6,74.4,69.8,68.5,59.9,30.1,25.7,18.0,-4.6,-4.7。
HRMS(ESI)m/z精确质量计算C20H31O8SSi[M+H]+459.1503,实测值459.1505。
实施例4
向装有搅拌棒、经烘箱干燥的250mL圆底烧瓶装入保护的肌醇底物(0.81g,2.63mmol,1.0eq.)、双三苯基膦硼氢化亚铜(157.8mg,0.26mmol,10mol％)、手性配体L1(179.3mg,0.32mmol,12mol％)、碳酸银(435.5mg,1.58mmol,0.6eq.)、分子筛(0.4g)，然后加入干燥氯仿(50mL)。室温条件下搅拌5分钟后加入苯磺酰氯(0.4mL,3.16mmol,1.2eq.)。室温条件下反应2天，用铺有硅藻土的过滤装置过滤，滤液浓缩并通过硅胶柱色谱纯化(石油醚/乙酸乙酯＝4/1)。得到白色固体(0.92g,产率：78％，ee：86％)。
表征数据：
HPLC条件:Chiralcel OD(正己烷/异丙醇＝95/5,流速0.5mL/min,λ＝214nm),tR(major)＝31.82min,tR(minor)＝24.73min。
1H NMR(400MHz,CDCl3)δ8.43–8.12(m,2H),7.97–7.73(m,1H),7.88–7.66(m,4H),7.33–7.38(m,3H),5.35(td,J＝4.0,1.7Hz,1H),4.86–4.76(m,1H),4.56–4.50(m,1H),4.44–4.37(m,1H),4.31(t,J＝1.8Hz,1H),4.29–4.26(m,1H),2.80(s,3H)2.55(d,J＝6.6Hz,1H)。
13C NMR(100MHz,CDCl3)δ165.5,136.2,135.7,134.0,129.9,129.7,128.4,127.9,126.0,107.8,76.0,75.6,74.7,69.9,67.7,59.6,38.8,25.9。
HRMS(ESI)m/z精确质量计算C21H21O9S[M+H]+449.0901,实测值449.0900。
实施例5
向装有搅拌棒、经烘箱干燥的250mL圆底烧瓶装入保护的肌醇底物(1.0g,2.63mmol,1.0eq.)、双三苯基膦硼氢化亚铜(157.8mg,0.26mmol,10mol％)、手性配体L1(179.3mg,0.32mmol,12mol％)、碳酸银(435.5mg,1.58mmol,0.6eq.)、分子筛(0.4g)，然后加入干燥氯仿(50mL)。室温条件下搅拌5分钟后加入环己基磺酰氯(0.46mL,3.16mmol,1.2eq.)。室温条件下反应2天，用铺有硅藻土的过滤装置过滤，滤液浓缩并通过硅胶柱色谱纯化(石油醚/乙酸乙酯＝4/1)。得到白色固体(1.14g,产率：82％，ee：90％)。
表征数据：
HPLC条件:Chiralcel OD(正己烷/异丙醇＝95/5,流速0.5mL/min,λ＝214nm),tR(major)＝21.75min,tR(minor)＝13.33min。
1H NMR(400MHz,CDCl3)δ8.01–7.91(m,2H),7.73–7.64(m,1H),7.33–7.30(m,2H),5.35(td,J＝4.0,1.7Hz,1H),4.63–4.60(m,1H),4.54–4.32(m,1H),4.33–4.25(m,1H),4.45(t,J＝1.8Hz,1H),4.16–4.13(m,1H),2.43(d,J＝6.6Hz,1H),2.33–2.23(m,1H),1.53–1.49(m,4H),1.46–1.43(m,4H),1.33–1.25(m,2H),0.92(s,9H),0.13(s,3H),0.10(s,3H)。
13C NMR(100MHz,CDCl3)δ135.1,129.1,129.0,125.3,107.1,75.0,74.0,73.2,69.3,67.2,59.0,31.9,25.6,22.1,21.5,20.3,18.1,-4.66,-4.70。
HRMS(ESI)m/z精确质量计算C25H39O8SSi[M+H]+527.2129,实测值527.2125。
实施例6
向装有搅拌棒、经烘箱干燥的250mL圆底烧瓶装入保护的肌醇底物(1mmol)、双三苯基膦硼氢化亚铜(0.01mmol)、手性配体L3(0.02mmol)、碳酸银(0.35mmol)、分子筛(0.2g)，然后加入干燥四氯化碳(50mL)。室温条件下搅拌5分钟后加入环己基磺酰氯(3mmol)。室温条件下反应2天，用铺有硅藻土的过滤装置过滤，滤液浓缩并通过硅胶柱色谱纯化(石油醚/乙酸乙酯＝4/1)。得到白色固体(产率：70％，ee：86％)。
实施例7
向装有搅拌棒、经烘箱干燥的250mL圆底烧瓶装入保护的肌醇底物(1mmol)、双三苯基膦硼氢化亚铜(0.3mmol)、手性配体L6(0.28mmol)、碳酸银(1mmol)、分子筛(0.2g)，然后加入干燥二氯乙烷(50mL)。-10℃条件下搅拌5分钟后加入环己基磺酰氯(1mmol)。-10℃条件下反应2天，用铺有硅藻土的过滤装置过滤，滤液浓缩并通过硅胶柱色谱纯化(石油醚/乙酸乙酯＝4/1)。得到白色固体(产率：87％，ee：88％)。
实施例8
向装有搅拌棒、经烘箱干燥的250mL圆底烧瓶装入保护的肌醇底物(1mmol)、双三苯基膦硼氢化亚铜(0.05mmol)、手性配体L9(0.08mmol)、碳酸银(0.5mmol)、分子筛(0.2g)，然后加入干燥二氯甲烷(50mL)。0℃条件下搅拌5分钟后加入环己基磺酰氯(2mmol)。0℃条件下反应2天，用铺有硅藻土的过滤装置过滤，滤液浓缩并通过硅胶柱色谱纯化(石油醚/乙酸乙酯＝4/1)。得到白色固体(产率：76％，ee：90％)。
以上所述，仅为本发明的具体实施方式，但本发明的保护范围并不局限于此，任何属于本技术领域的技术人员在本发明揭露的技术范围内，可轻易想到的变化或替换，都应涵盖在本发明的保护范围之内。因此，本发明的保护范围应该以权利要求的保护范围为准。

Claims (1)

1.一种金鸡纳碱衍生的NNP配体，具有以下结构：
。
CN202111546885.1A 2021-12-16 2021-12-16 金鸡纳碱衍生的nnp配体及其制备方法与用途 Active CN114380863B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111546885.1A CN114380863B (zh) 2021-12-16 2021-12-16 金鸡纳碱衍生的nnp配体及其制备方法与用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111546885.1A CN114380863B (zh) 2021-12-16 2021-12-16 金鸡纳碱衍生的nnp配体及其制备方法与用途

Publications (2)

Publication Number Publication Date
CN114380863A CN114380863A (zh) 2022-04-22
CN114380863B true CN114380863B (zh) 2023-09-22

Family

ID=81198768

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111546885.1A Active CN114380863B (zh) 2021-12-16 2021-12-16 金鸡纳碱衍生的nnp配体及其制备方法与用途

Country Status (1)

Country Link
CN (1) CN114380863B (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110590841A (zh) * 2019-08-29 2019-12-20 南方科技大学 一种氮磷配体及其制备方法和用途
CN110627610A (zh) * 2019-08-29 2019-12-31 南方科技大学 一种催化不对称交叉偶联合成炔的方法
CN114213460A (zh) * 2021-11-01 2022-03-22 贵州医科大学 一种用于酮不对称氢化反应或转移加氢反应的手性氮氮膦化合物、制备方法及应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110590841A (zh) * 2019-08-29 2019-12-20 南方科技大学 一种氮磷配体及其制备方法和用途
CN110627610A (zh) * 2019-08-29 2019-12-31 南方科技大学 一种催化不对称交叉偶联合成炔的方法
CN114213460A (zh) * 2021-11-01 2022-03-22 贵州医科大学 一种用于酮不对称氢化反应或转移加氢反应的手性氮氮膦化合物、制备方法及应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Cu-catalysed enantioselective radical heteroatomic S–O cross-coupling";Yong-Feng Cheng等;《Nature Chemistry》;第15卷;第395-404页 *

Also Published As

Publication number Publication date
CN114380863A (zh) 2022-04-22

Similar Documents

Publication Publication Date Title
US5008457A (en) Chiral phospholane transition metal catalysts
US5012002A (en) 2,2'-bis(di-(m-tolyl)phosphino)-1,1'-binaphthyl
US5457219A (en) Phosphorus compounds
JP5968439B2 (ja) スピロベンジルアミン−ホスフィン及びその製造方法並びにその使用
de Vries et al. Stereoselective reduction of prochiral ketones, using aluminum hydride reagents prepared from lialh4 and chiral diethanolamines.
CN114380863B (zh) 金鸡纳碱衍生的nnp配体及其制备方法与用途
JP6476497B2 (ja) 光学活性化合物の製造方法、及び新規な金属−ジアミン錯体
US5177230A (en) Chiral phospholane transistor metal catalysts
CN111423351B (zh) 手性铜复合物及其制备方法和应用
JP2816555B2 (ja) 新規なホスフイノピロリジン化合物およびそれを用いる不斉合成法
Bauer et al. Sugar-based monodentate phosphoramidite ligands for Cu-catalyzed enantioselective conjugate addition to enones
CN113831366B (zh) 一种金鸡纳碱类配体及其制备方法与用途
JP2010500295A (ja) ２，２’，６，６’−四置換アミノホスフィン配位子及びその合成方法
CN107226829B (zh) 一种含二茂铁基团的膦氧配体的制备方法
CN114702445B (zh) 一种三齿氮配体及其合成方法与用途
CN115707518B (zh) 一种手性双核铑金属催化剂及其制备方法和应用
CN114394919B (zh) 一种合成手性甘油磺酸酯的方法
JP3431749B2 (ja) 新規な１−置換−２−ジフェニルホスフィノナフタレンおよびこれを配位子とする遷移金属錯体
JP7186429B2 (ja) キラルボラート塩及びその製造方法
CN114096547B (zh) 光学活性双膦基甲烷、其制造方法以及过渡金属络合物和不对称催化剂
US8822680B2 (en) Paracyclophane-based ligands, their preparation and use in catalysis
JP4282788B2 (ja) 新規なジフェニルアルシン類
JPH08217775A (ja) 新規クラウンチオエーテル及びその遷移金属錯体並びにこれを用いる光学活性アルコールの製造方法
JPWO2008059960A1 (ja) クォータピリジン誘導体の製造方法及びその中間体
US5849961A (en) Optically active 1,1'-biphenanthryl-2,2'-diol, process for preparing the same, and resolving reagent comprising the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant